MedTrace Logo

Efficacy of Prednisone In the Treatment of Ocular Myasthenia

NCT00995722 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 11

Last updated 2017-06-02

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to evaluate the efficacy and tolerability of prednisone in patients diagnosed with ocular myasthenia.

Funding Source - FDA OOPD

Conditions

  • Ocular Myasthenia Gravis

Interventions

DRUG

Prednisone

Prednisone will be adjusted based on combined measures of tolerability and efficacy. Capsules will contain 10mg of prednisone.

DRUG

Placebo

Placebo dosages will be adjusted based on combined measures of tolerability and efficacy. Capsules will contain matching placebo.

Sponsors & Collaborators

  • University of Miami

    collaborator OTHER

  • University of Rochester

    collaborator OTHER

  • Michael Benatar

    lead OTHER

Principal Investigators

  • Michael Benatar, MBChB, DPhil · University of Miami

  • Gil Wolfe, MD · State University of New York at Buffalo

  • Donald Sanders, MD · Duke University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-12-31
Primary Completion
2013-10-31
Completion
2013-10-31

Countries

  • United States
  • Canada

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00995722 on ClinicalTrials.gov